Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2008 by University of Aarhus.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT00625001
First received: February 19, 2008
Last updated: NA
Last verified: February 2008
History: No changes posted

February 19, 2008
February 19, 2008
November 1994
October 1996   (final data collection date for primary outcome measure)
Bone Mineral Density in columna lumbalis, collum femoris and distal ulnae Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm. [ Time Frame: Evey 5 years ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome
Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome

Turner Syndrome (TS) is associated with osteopenia and osteoporosis. Reduced bone mineral density (BMD) and increased risk of fractures are present in many younger and middle-aged women with TS. The objective is therefore to describe longitudinal changes in BMD in TS.

The study is an observational follow-up study. Examinations at baseline, after 5 and 10 years.

Bone mineral density is measured by dual energy x-ray absorptiometry (DEXA) and bone turnover by bone markers.

Main Outcome Measures: Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Blood samples

Non-Probability Sample

Women with Turner syndrome

Turner Syndrome
Not Provided
  • 1
    Women with Turner syndrome
  • 2
    Healthy control women
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
54
June 2010
October 1996   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Turner syndrome verified by karyotyping

Exclusion Criteria:

  • untreated hypothyroidism or hyperthyroidism
  • present or past malignant diseases
  • clinical liver disease
  • treatment with drugs known to interfere with bone metabolism (e.g. glucocorticoids)
Female
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00625001
1994/2424
No
MD, Dr. Med. Sci Claus Gravholt, University of Aarhus
University of Aarhus
Not Provided
Not Provided
University of Aarhus
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP